Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Who's in charge here?

WASHINGTON - Genzyme Tissue Repair (GENZL) on Friday announced that it voluntarily halted its Carticel cartilage cell service pending resolution of a dispute over regulatory jurisdiction over

Read the full 275 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE